Despite controversy regarding the role of glucagon in metabolic disorders associated with diabetes, the recognized importance of hyperglucagonemia in the pathophysiology of T1D and T2D fostered the development of therapeutic strategies aimed at glucagon action reduction (165, 167). The gene discussed is GCG; the disease is metabolic disease.